Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

A Factor VIII Fusion with an Inactivated FIX Generates a Biologically Active Molecule with Delayed Clearance in a FVIII/VWF Knockout Mouse Model

Oladipo Jude Akinwale, MSc,BSc, Ian Wilkinson, PhD, Christine Hough, PhD, David Lillicrap, MD FRCPC, Michael Makris, MD, Richard Ross, MD FRCP

Blood (2017) 130 (Supplement 1): 2344.

https://doi.org/10.1182/blood.V130.Suppl_1.2344.2344

Published: 2017

Journal Articles

Pharmacokinetic Behavior of IB1001, An Investigational Recombinant Factor IX, in Patients with Hemophilia B: Repeat Pharmacokinetic Study and Subgroup Analysis

Uri Martinowitz, MD, Amy D. Shapiro, MD, Doris V. Quon, MD, PhD, Miguel Antonio Escobar, MD, Christine L Kempton, MD, MSc, Peter Collins, MD, Pratima Chowdary, MD, Michael Makris, MD, Pier Mannuccio Mannucci, MD, Massimo Morfini, MD, Leonard A. Valentino, MD, Edward D. Gomperts, MD, Martin Lee, PhD

Blood (2011) 118 (21): 2267.

https://doi.org/10.1182/blood.V118.21.2267.2267

Published: 2011

Journal Articles

Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients: Results From a Prospective Registry of European Hemophilia B Patients.

Pablo Rendo, MD, Erik Berntorp, MD, PhD, David M. Keeling, MD, Michael Makris, MD, Cedric R. Hermans, MD., PhD., Ereline Pauline Mauser-Bunschosten, Roberto Musso, Annarita Tagliaferri, Carl Kollmer, James Baumann, Robert Charnigo

Blood (2010) 116 (21): 3664.

https://doi.org/10.1182/blood.V116.21.3664.3664

Published: 2010

Journal Articles

Thrombin Generation Is Normal in Most Patients with Cirrhosis despite a Prolonged INR.

Alexander Gatt, MD, MRCP, FRCPath, Anne Riddell, Vincenza Calvaruso, Michael Makris, MD, Edward Tuddenham, Andrew Burroughs

Blood (2008) 112 (11): 1826.

https://doi.org/10.1182/blood.V112.11.1826.1826

Published: 2008

Journal Articles

Prothrombin Complex Concentrate for Warfarin Reversal: A Single Dose Is Effective for All INRs >4.5.

Alexander Gatt, MD, MRCP, FRCPath, Anne Riddell, Joost J van Veen, Steve Kitchen, Edward Tuddenham, Michael Makris, MD

Blood (2008) 112 (11): 1985.

https://doi.org/10.1182/blood.V112.11.1985.1985

Published: 2008

Journal Articles

Platelet-Activating Anti-Platelet Factor 4/Polyanion Antibodies without Preceding Heparin Therapy: A Transient Autoimmune Disorder Resembling Heparin-Induced Thrombocytopenia (“Spontaneous HIT”).

Theodore E. Warkentin, MD, Richard M. Jay, MD, Michael Makris, MD, John G. Kelton, MD

Blood (2006) 108 (11): 1047.

https://doi.org/10.1182/blood.V108.11.1047.1047

Published: 2006

Journal Articles

Reversal of Anticoagulation as Assessed by Thrombin Generation Measurement.

Alex Gatt, MD, Joost van Veen, MD, Peter Cooper, Steve Kitchen, PhD, Michael Makris, MD

Blood (2006) 108 (11): 876.

https://doi.org/10.1182/blood.V108.11.876.876

Published: 2006

Journal Articles

A Novel Protac®-Modified Thrombin Generation Assay To Identify Individuals at Higher Thrombotic Risk.

Alex Gatt, MD, Joost van Veen, MD, Peter Cooper, Steve Kitchen, PhD, Michael Makris, MD

Blood (2006) 108 (11): 1472.

https://doi.org/10.1182/blood.V108.11.1472.1472

Published: 2006

NARROW

A Factor VIII Fusion with an Inactivated FIX Generates a Biologically Active Molecule with Delayed Clearance in a FVIII/VWF Knockout Mouse Model

Pharmacokinetic Behavior of IB1001, An Investigational Recombinant Factor IX, in Patients with Hemophilia B: Repeat Pharmacokinetic Study and Subgroup Analysis

Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients: Results From a Prospective Registry of European Hemophilia B Patients.

Thrombin Generation Is Normal in Most Patients with Cirrhosis despite a Prolonged INR.

Prothrombin Complex Concentrate for Warfarin Reversal: A Single Dose Is Effective for All INRs >4.5.

Platelet-Activating Anti-Platelet Factor 4/Polyanion Antibodies without Preceding Heparin Therapy: A Transient Autoimmune Disorder Resembling Heparin-Induced Thrombocytopenia (“Spontaneous HIT”).

Reversal of Anticoagulation as Assessed by Thrombin Generation Measurement.

A Novel Protac®-Modified Thrombin Generation Assay To Identify Individuals at Higher Thrombotic Risk.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only